Allogeneic mesenchymal stromal cell therapy on primary graft dysfunction after lung transplantation.
Qayyum AA., Lund TK., Jensen PB., Jensen K., Haack-Sørensen M., Ekblond A.
Randomized Controlled Trial with a reported sample of 31 on Immune Modulation, published in JHLT Open (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Randomized Controlled Trial
- Journal
- JHLT Open (2025)
- Country
- United States
- Reported sample size
- 31
- Source database
- PubMed
- PMID
- 40247997
- PMCID
- PMC12005341
- DOI
- 10.1016/j.jhlto.2025.100254
- NCT
- NCT04714801
- Citations
- 2
Abstract (original English)
Background Primary graft dysfunction (PGD) is common in lung transplantation affecting 15-30% of recipients. It represents a multifactorial injury to the transplanted lung within the first 72 hours after transplantation.We aimed to investigate clinical safety and efficacy of allogeneic adipose tissue-derived stromal cells (ASCs), as an add-on therapy in patients undergoing double lung transplantation. Methods Single center, double-blinded, investigator-initiated randomized phase I/II study with intravenous infusion of either ASCs or placebo within two hours after lung transplantation. A total of 31 patients were included and randomized 1:1:1 to either 200 million or 100 million ASCs, or placebo infusion.The primary endpoint was difference in PGD grade 72 hours after transplantation between groups. Results No significant differences in PGD were seen between the 3 groups 72 hours after lung transplantation (P=0.426). Combined ASC groups compared to placebo group did not show any difference in PGD 72 hours after transplantation (P=0.252). A reduced progression in PGD from day 1 to day 3 and day 2 to day 3 was observed between the ASC treated patients and patients in the placebo group (P=0.034 and P=0.034, respectively). There were no significant differences in number of serious adverse events or in secondary endpoints such as kidney function, lung function, or quality-of-life betw
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewPubMed
Regeneration in Aesthetic Medicine: Mechanisms, Evidence, and Clinical Boundaries.
Systematic Review on Skin Aging, Immune Modulation, published in J Cosmet Dermatol (2026) — summary generated from the PubMed abstract.
- 2026
J Cosmet Dermatol - Level ASystematic ReviewEurope PMC
Molecular and Regenerative Effects of Platelet-Rich Plasma and Related Hemocomponents in Animal Models of Liver Injury-A Systematic Review
Systematic Review on Immune Modulation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci - Level ASystematic ReviewPubMed
Stromal Vascular Fraction in Bone Healing: A Systematic Review of Clinical Evidence and Potential Implications in Skull Base Reconstruction and Cranioplasty.
Systematic Review with a reported sample of 214 on Chronic Wound, Immune Modulation, published in J Craniofac Surg (2026) — summary generated from the PubMed abstract.
- 2026
- n = 214
J Craniofac Surg - Level AMeta-analysisEurope PMC
The efficacy and safety of MSCs in GVHD prevention and the treatment of SR-aGVHD: a systematic review and meta-analysis of randomized controlled trials
Meta-analysis on Immune Modulation, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Res Ther - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol